Cardiac Diseases

Many different factors and conditions can cause CKD including:

Patients with whatever the aetiology have irreversible loss of cardiac tissue and ultimately have a significantly decreased left ventricular function. The myocardium does indeed have a limited regenerative capacity

Stem cells from bone marrow or adipose tissue injected into areas of low perfusion or scars in the cardiac tissue may become populated with angiogenic stem cells, improving blood supply in the area and reducing myocardial scar size.

The benefits are postulated to come from their influence on neovascularization of the ischemic tissue and their protection of resident cells.The paracrine and secretion of various angiogenic and survival growth factors further enhance the recovery of injured myocardium

Procedure significantly improves left ventricular cardiac function and decreases mortality.

How it is done

The goal is to transplant at the cells in infracted, ischemic, hypo contractile myocardium directly or indirectly.

In Acute MI it is done with 3 to 7 days

The possible routes are:

Intracoronary Transplantation: cells can be administered into coronary artery just like a dye as in routine angiographic procedures. The cells get distributed into whole of myocardium through branches of coronary artery

Intramyocardially through catheter

The cells can also be administered intra-myocardial into the targeted treatment region using the special catheter delivery system under fluoroscopic guidance.

80 %patients reach close to Six-minute walk test (6MWT) of >400 meters
70 % patients achieve Minnesota Living with Heart Failure (MLWHF) score of <20
74 % of patients achieve Left ventricular ejection fraction to mean of 45 at 6 months
75 %Reach (NYHA) Class II from pre-treatment IV
50% of patients have improvement in B-type natriuretic peptide (BNP) or NT pro-BNP.
60 % had good reduction in Ascites
60 % patients report improvement in Myocardial wall thickness to > 10 mm at injected site.

The website contains no medical advice. All statements and opinions provided by the website are for educational and informational purposes. ||The treatment centres associated with Revita lifesciences provide surgical procedure only and are not involved in use or manufacture of any investigational drug ||Revita does not claim that any application or potential application, using autologous stem cells are approved by the FDA. We do not claim that these procedures work for any listed nor unlisted condition, intended or implied.||It’s important for potential patients to do their own research based on the options we present so that one can make an informed decision. Any decision to participate in experimental protocol is completely voluntary ||

A to z of clinical and application based stem cell science under one roof

Cardiac Diseases

Cardiac Diseases

How it is done

What to expect